The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma
出版年份 2023 全文链接
标题
The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volume -, Issue -, Pages ijgc-2023-004739
出版商
BMJ
发表日期
2023-11-01
DOI
10.1136/ijgc-2023-004739
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- GOG 3026 A phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: A GOG foundation study (001)
- (2023) Brian Slomovitz et al. Gynecologic Oncology
- A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study
- (2022) Brian M. Slomovitz et al. GYNECOLOGIC ONCOLOGY
- Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study
- (2022) Massimo Cristofanilli et al. CLINICAL CANCER RESEARCH
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
- (2022) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2022) A. Oaknin et al. ANNALS OF ONCOLOGY
- A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer
- (2022) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of CDK4/6 Inhibitors: A Five Years Update
- (2021) Alessandra Ammazzalorso et al. MOLECULES
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
- (2021) Yen-Shen Lu et al. CLINICAL CANCER RESEARCH
- Endometrial cancer
- (2021) Vicky Makker et al. Nature Reviews Disease Primers
- G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
- (2020) Kaitlyn J. Andreano et al. BREAST CANCER RESEARCH AND TREATMENT
- CDK4/RB/E2Fs axis as potential therapeutic target of endometrial cancer
- (2020) Jing Hu et al. BIOMEDICINE & PHARMACOTHERAPY
- The application and prospect of CDK4/6 inhibitors in malignant solid tumors
- (2020) Qi Du et al. Journal of Hematology & Oncology
- 334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection
- (2020) I. Bulat et al. ANNALS OF ONCOLOGY
- LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
- (2020) M.R. Mirza et al. ANNALS OF ONCOLOGY
- Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
- (2020) Michela Piezzo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
- (2020) Nicole Concin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
- (2020) Willem Jan van Weelden et al. HUMAN PATHOLOGY
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
- (2019) H. S. Rugo et al. BREAST CANCER RESEARCH AND TREATMENT
- Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review
- (2019) Willem Jan van Weelden et al. Frontiers in Oncology
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Estrogen Receptor‐Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance
- (2018) Adam M. Brufsky et al. ONCOLOGIST
- Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
- (2017) David M. Gershenson et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
- (2017) John E. Bisi et al. Oncotarget
- Endometrial cancer
- (2016) Philippe Morice et al. LANCET
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
- (2012) David M. Gershenson et al. GYNECOLOGIC ONCOLOGY
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
- (2008) Kathleen M. Schmeler et al. GYNECOLOGIC ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now